The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin von HE, Y.-L, SABO, R, CAMPESTRINI, J, WANG, Y, LIGUEROS-SAYLAN, M, LASSETER, K. C, DILZER, S. C, HOWARD, D, DOLE, W. P

Volltext

Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers von Lasseter, K, Dilzer, S, Jansat, J.M, Garcia Gil, E, Caracta, C.F, Ortiz, S

Volltext

Disposition of Caspofungin: Role of Distribution in Determining Pharmacokinetics in Plasma von STONE, Julie A, XIN XU, SINGH, Romi, DELUNA, Florencia, DILZER, Stacy C, LASSETER, Kenneth C, WINCHELL, Gregory A, DEUTSCH, Paul J, PEARSON, Paul G, MIGOYA, Elizabeth M, MISTRY, Goutam C, LIWEN XI, MILLER, Alisha, SANDHU, Punam

Volltext

FTY720 Pharmacokinetics in Mild to Moderate Hepatic Impairment von Kovarik, J. M., Schmouder, R. L., Serra, D., Wang, Y., Wiegand, H., Dilzer, S. C., Lasseter, K. C.

Volltext

Interactions between Simvastatin and Troglitazone or Pioglitazone in Healthy Subjects von Prueksaritanont, Thomayant, Vega, José M., Zhao, Jamie, Gagliano, Kathleen, Kuznetsova, Olga, Musser, Bret, Amin, Raju D., Liu, Lida, Roadcap, Brad A., Dilzer, Stacy, Lasseter, K. C., Rogers, J. Douglas

Volltext

Pharmacokinetics of Etoricoxib in Patients with Hepatic Impairment von Agrawal, Nancy G. B., Rose, Mark J., Matthews, Catherine Z., Woolf, Eric J., Porras, Arturo G., Geer, Leslie A., Larson, Patrick J., Cote, Josee, Dilzer, Stacy C., Lasseter, Kenneth C., Alam, Imtiaz, Petty, Kevin J., Gottesdiener, Keith M.

Volltext

Pharmacokinetics and Pharmacodynamics of Zolmitriptan in Patients with Mild to Moderate Hypertension: A Double-Blind, Placebo-Controlled Study von Smith, Deborah A., Cleary, Elena W., Watkins, Stephanie, Huffman, Cameron S., Dilzer, Stacy C., Lasseter, Kenneth C.

Volltext

Potential for Interactions between Caspofungin and Nelfinavir or Rifampin von STONE, Julie A, MIGOYA, Elizabeth M, LASSETER, Kenneth C, KRAFT, Walter K, GREENBERG, Howard, WALDMAN, Scott A, HICKEY, Lisa, WINCHELL, Gregory A, DEUTSCH, Paul J, GHOSH, Kalyan, FREEMAN, Amanda, SHENG BI, DESAI, Rajesh, DILZER, Stacy C

Volltext

PII-49Lack of clinically significant effect of moderate hepatic insufficiency on the pharmacokinetics of MK-0431 (sitagliptin), a dipeptidyl-peptidase-IV (DPP-IV) inhibitor von STEVENS, C, BERGMAN, A, LIU, Q, LUO, W, WANG, A, ZENG, W, LASSETER, K, DILZER, S, WAGNER, J, HERMAN, G

Volltext

PII-49 von Stevens, C., Bergman, A. J., Liu, Q., Luo, W., Wang, A. Q., Zeng, W., Lasseter, K. C., Dilzer, S., Wagner, J. A., Herman, G. A., Migoya, E.

Volltext

Pharmacokinetics of Sirolimus (Rapamycin) in Subjects With Mild to Moderate Hepatic Impairment von Zimmerman, James J., Lasseter, Kenneth C., Lim, Heng-Keang, Harper, Dawn, Dilzer, Stacey C., Parker, Vernon, Matschke, Kyle

Volltext

Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment von Kovarik, J

Volltext

Pharmacokinetics of Long-Acting Naltrexone in Subjects With Mild to Moderate Hepatic Impairment von Turncliff, Ryan Z., Dunbar, Joi L., Dong, Qunming, Silverman, Bernard L., Ehrich, Elliot W., Dilzer, Stacy C., Lasseter, Kenneth C.

Volltext

Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment von Kovarik, John M., Sabia, Helene D., Figueiredo, Joaquim, Zimmermann, Heidrun, Reynolds, Christine, Dilzer, Stacy C., Lasseter, Kenneth, Rordorf, Christiane

Volltext

Pharmacokinetics and safety of Ebastine in patients with impaired hepatic function compared with Healthy volunteers: A phase I open-label study von LASSETER, Kenneth C, DILZER, Stacy C, VARGAS, Ramon, WALDMAN, Scott, NOVECK, Robert J

Volltext

Active-site heterogeneity in subunits of horseshoe crab hemocyanin (Limulus polyphemus) von Topham, R., Tesh, S., Dilzer, S., Bonaventura, C., Bonaventura, J.

Volltext

Upcoming FDA approval decisions in Q1 2025 von Dilzer, Kaniaw

Volltext

Upcoming market catalysts in Q3 2024 von Dilzer, Kaniaw

Volltext

Upcoming market catalysts in Q1 2023 von Dilzer, Kaniaw

Volltext

Upcoming market catalysts in Q1 2021 von Dilzer, Kaniaw

Volltext